# Sorafenib

Source: https://nuclide.cc/drugs/sorafenib/  
Nuclide record `sorafenib` (Agent). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

The first drug ever to extend life in advanced liver cancer (2007), now mostly a comparator arm that newer combinations are measured against.

## Summary

SHARP: OS 10.7 vs 7.9 months versus placebo (HR 0.69). Standard first-line therapy for a decade until REFLECT (lenvatinib non-inferior) and IMbrave150 (atezolizumab-bevacizumab superior). Also approved in RCC and radioiodine-refractory thyroid cancer. Hand-foot skin reaction and diarrhoea dominate toxicity.

## Fields

- Kind: Agent
- Status: approved
- Last checked: 2026-09-07
- Brand: Nexavar
- Modality: Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, RAF)
- Mechanism: Oral inhibitor of VEGFR1-3, PDGFR-β, KIT, FLT3 and RAF kinases; anti-angiogenic and anti-proliferative.
- Approvals: US 2005: Advanced RCC; US 2007: Unresectable HCC; US 2013: Radioiodine-refractory differentiated thyroid cancer
- Dosing: Oral; 400 mg twice daily continuously
- Toxicity (grade 3+): Diarrhoea 8%; Hand-foot skin reaction 8%; Fatigue 4%

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Sorafenib
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sorafenib

## Connected records

- indications: [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/), [Renal cell carcinoma](https://nuclide.cc/indications/rcc/), [Thyroid cancer](https://nuclide.cc/indications/thyroid/)
- companies: [Bayer](https://nuclide.cc/companies/bayer/)
- terms: [Radioiodine therapy (I-131)](https://nuclide.cc/terms/radioiodine-term/)
- trials: [SARAH and SIRveNIB](https://nuclide.cc/trials/sarah-sirvenib/)
- pairings: [Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma](https://nuclide.cc/pairings/tare-vs-sorafenib-caution/)

---
JSON: https://nuclide.cc/api/v1/entities/sorafenib.json